Patient Case: Reducing The Risk for Adverse Events in a T2DM Patient with HFrEF, CKD, and Existing ASCVD
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging.
  • CMHC
  • Self-study / Enduring
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation